| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 依伐卡托; Ivacaftor (VX-770) | CFN60053 | 873054-44-5 | C24H28N2O3 = 392.49 | 5mg | QQ客服：1457312923 |
| 克唑替尼; Crizotinib (PF-02341066) | CFN60054 | 877399-52-5 | C21H22Cl2FN5O = 450.34 | 5mg | QQ客服：215959384 |
| 维利帕尼; Veliparib (ABT-888) | CFN60055 | 912444-00-9 | C13H16N4O = 244.29 | 5mg | QQ客服：3257982914 |
| Dactolisib (BEZ235) ; Dactolisib (BEZ235) | CFN60056 | 915019-65-7 | C30H23N5O = 469.55 | 5mg | QQ客服：1457312923 |
| 恩杂鲁胺; Enzalutamide (MDV3100) | CFN60057 | 915087-33-1 | C21H16F4N4O2S = 464.44 | 5mg | QQ客服：215959384 |
| 维罗非尼; Vemurafenib (PLX4032) | CFN60058 | 918504-65-1 | C23H18ClF2N3O3S = 489.92 | 5mg | QQ客服：3257982914 |
| PLX-4720; PLX-4720 | CFN60059 | 918505-84-7 | C17H14ClF2N3O3S = 413.83 | 5mg | QQ客服：2159513211 |
| 生根粉263; Navitoclax (ABT-263) | CFN60060 | 923564-51-6 | C47H55ClF3N5O6S3 = 974.61 | 5mg | QQ客服：2159513211 |
| 依鲁替尼; Ibrutinib (PCI-32765) | CFN60061 | 936563-96-1 | C25H24N6O2 = 440.5 | 5mg | QQ客服：2056216494 |
| 鲁玛卡托; Lumacaftor (VX-809) | CFN60062 | 936727-05-8 | C24H18F2N2O5 = 452.41 | 5mg | QQ客服：3257982914 |
| 鲁索利替尼; Ruxolitinib (INCB018424) | CFN60063 | 941678-49-5 | C17H18N6 = 306.37 | 5mg | QQ客服：1413575084 |
| SCH772984; SCH772984 | CFN60064 | 942183-80-4 | C33H33N9O2 = 587.67 | 5mg | QQ客服：2159513211 |
| 布帕尼西; Buparlisib (BKM120) | CFN60065 | 944396-07-0 | C18H21F3N6O2 = 410.39 | 5mg | QQ客服：215959384 |
| Adavosertib (MK-1775); Adavosertib (MK-1775) | CFN60066 | 955365-80-7 | C27H32N8O2 = 500.6 | 5mg | QQ客服：215959384 |
| Pictilisib (GDC-0941); Pictilisib (GDC-0941) | CFN60067 | 957054-30-7 | C23H27N7O3S2 = 513.64 | 5mg | QQ客服：3257982914 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)